KemPharm, Inc. a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, FDA-approved drugs.

According to the Complaint, it is alleged in violation of the Securities Act, Defendants negligently issued untrue statements of material facts and omitted to state material facts required to be stated from the Registration Statement and incorporated incomplete Offering Materials that the Company filed with the SEC in support of the Offering.

On July 17, 2017, this case was remanded to the Iowa District Court for Johnson County.